Phone Line Dropped Calls

SIU Medicine's primary phone line, 217-545-8000, is experiencing intermittent dropped calls. We apologize for this inconvenience and are working to correct this issue as soon as possible.

Close up of Leica Microscope
Blog

Finding the starting line for Alzheimer's

Published Date:

Where should research start in solving Alzheimer's? That's a tricky question to answer. What exactly are researchers looking for when trying to solve the Alzheimer’s puzzle?

“It depends on the researcher,” says Kevin Hascup, PhD. “Really, the tried and true biomarkers are three — amyloid, tau and neurofilament light chain, or what is known as A/T/N.”

A biomarker (molecules in blood, body fluid, and tissue) helps with understanding the changes that occur with age and disease onset. Each of the three A/T/N biomarkers progress in its own way in aging and with dementia. But no matter which biomarker scientists focus on, they are driving the field to explore the first signs of cognitive decline. The thought is, the faster we can identify that change, more effective treatments can be created.

Remote video URL

 

Agreeing when it starts? That's a different and costly question, not only for researchers, but also patients.

"That’s the problem. A PET scan could be $6,000 to $10,000 here in Springfield, so most people can’t afford that, and insurance isn’t going to pay for it unless you’re in a study,” Hascup said. “So, what the field considers early is identifying the first sign of cognitive decline.

“That’s the tried and true method, but where scientists really want to drive the field toward is the biomarker that indicates changes before the cognitive decline is observed. That way we can intervene faster.”

There's also the question of which A/T/N biomarker provides that first and best clue to cognitive decline. Amyloid is generally considered to appear first. Tau correlates with disease severity or disease progression. The amount present in the brain is determined primarily through imaging. Then you have what’s referred to as neurofilament lightchain, which is determined through cerebrospinal fluid (CSF). It’s also the least expensive of the tests, and the field is quickly looking at specific CSF markers of tau as well.

All of this was designed in the last decade to give clinicians a better understanding of where they are in disease progression, Hascup said.

In addition, a significant amount of research has been moving into markers of inflammation. This includes risk factors such as toxins you inhale, obesity, hypertension, etc. and results in some kind of chronic inflammatory state. Over time, these small molecules, even if it’s just fat in your stomach, can move into your blood stream and cross into your blood. So, the more inflammation you have, the greater chance it's affecting the body as a whole.

To read more about biomarkers and how they help diagnose dementia, the National Institute on Aging provides additional information on types of biomarkers.

More from SIU Blog

tractor

Redefining Toughness: Cultivating Mental Health Awareness in Agriculture

In the heart of rural communities, where the fields stretch far and wide under the open sky, there exists a resilience ingrained in the very fabric of farming life. People often equate this resilience

Telehealth raises awareness for cervical cancer

Cervical cancer occurs most often in people over age 30. It results in about 11,500 new cases in the United States each year, and about 4,000 deaths, according to the Centers for Disease Control and
Woman on couch

How to deal with side effects from weight loss medications

Medications that help to lower blood sugar levels and promote weight loss have emerged as a promising new option for people who struggle with their weight. These drugs, known as GLP-1 agonists, have proven to be very effective. However, like many medications, they may come with gastrointestinal (GI) side effects that can impact a patient’s comfort and adherence.